Yan Fengting, Gopal Ajay K, Graf Solomon A
Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Pharmaceuticals (Basel). 2017 Mar 10;10(1):28. doi: 10.3390/ph10010028.
The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL.
套细胞淋巴瘤（MCL）的治疗格局正在迅速演变，越来越多地纳入新型生物靶向药物，与传统化疗药物相比，这些药物具有更好的疾病活性和更温和的毒性特征。MCL的初始强化治疗包括自体干细胞移植（SCT）巩固，旨在加深和延长疾病缓解期，但随后仍会复发。缓解期MCL患者自体SCT后的维持治疗采用低强度治疗，持续较长时间以改善疾病预后。靶向药物很适合这一领域，是大量临床研究的重点。本综述总结了该领域的最新进展及其对MCL治疗实践的潜在影响。
